Preimplantation Genetic Testing Market by Technology, Offering, Procedure Type, Application, End User

Description

List of Tables

The Preimplantation Genetic Testing Market was valued at USD 728.40 million in 2023, expected to reach USD 829.06 million in 2024, and is projected to grow at a CAGR of 14.56%, to USD 1,886.28 million by 2030.

Preimplantation Genetic Testing (PGT) is a cutting-edge procedure used to examine embryos for genetic diseases before implantation during assisted reproduction, aiming to reduce the risk of inherited conditions. Its necessity arises from the increasing demand for genetic disease prevention and healthy pregnancy outcomes, especially for individuals with a history of genetic disorders. The application of PGT predominantly lies in fertility clinics and hospitals that offer in vitro fertilization (IVF) services. The end-use scope ranges from couples at risk of passing on genetic mutations to those experiencing recurrent pregnancy losses or undergoing IVF. Key growth factors in this market include rising infertility rates, advances in genetic technologies, growing awareness about genetic disorders, and increasing acceptance of genetically informed reproductive choices. There is a continuous pour of investment in research and development, driving innovation and market expansion, with personalized medicine and precision healthcare gaining traction. Opportunities exist for businesses to innovate around non-invasive screening techniques and enhanced genetic analysis tools, representing the potential to widen adoption due to lower risks and increased accuracy. However, limitations include ethical considerations, high costs, strict regulations, and limited awareness in developing regions. Overcoming these factors requires extensive educational initiatives and strategic partnerships to drive adoption and affordability. Market players can focus on robust R&D efforts aimed at reducing costs while enhancing the efficacy and safety of PGT. Additionally, exploring the integration of artificial intelligence in data analysis could streamline processes and improve predictive accuracy. Emphasizing collaborations with academic institutions might spur key innovations. Businesses should also advocate for policies enhancing service accessibility while addressing ethical concerns to broaden their consumer base. By concentrating on these paths, firms can gain a competitive edge in the evolving landscape of PGT.

KEY MARKET STATISTICS
Base Year [2023]	USD 728.40 million
Estimated Year [2024]	USD 829.06 million
Forecast Year [2030]	USD 1,886.28 million
CAGR (%)	14.56%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Preimplantation Genetic Testing Market

The Preimplantation Genetic Testing Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

Market Drivers
- Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
- Increase in the rate of infertility and the rising number of fertility clinics worldwide
- Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
Market Restraints
- Limitation and risks associated with PGT
Market Opportunities
- Technological advancement in the field of preimplantation genetic analysis
- Emerging startup ecosystem and investments in the field of preimplantation genetic testing
Market Challenges
- Ethical constraints and Misuse of PGT

Porter's Five Forces: A Strategic Tool for Navigating the Preimplantation Genetic Testing Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Preimplantation Genetic Testing Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Preimplantation Genetic Testing Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Preimplantation Genetic Testing Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Preimplantation Genetic Testing Market

A detailed market share analysis in the Preimplantation Genetic Testing Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Preimplantation Genetic Testing Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Preimplantation Genetic Testing Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Key Company Profiles

The report delves into recent significant developments in the Preimplantation Genetic Testing Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, Agilent Technologies, Inc., Bio-Rad Laboratories, Inc., Bio-Techne Corporation, Bioarray S.L., EUROPE IVF International s.r.o., F. Hoffmann-La Roche AG, Genea Limited, GENETiKS, Illumina, Inc., Invicta Genetics, Invitae Corporation, Juno Genetics, US Inc., Laboratory Corporation of America Holdings, MedGenome Labs Ltd., Merck KGaA, Natera, Inc., NextGen Genetics Holdings, LLC, Ovation Fertility, PacGenomics, PerkinElmer, Inc., Progyny, Inc., Qiagen N.V., Quest Diagnostics Incorporated, Reproductive Genetic Innovations, LLC, SEQUENCE46, LLC, Sysmex Corporation, Takara Bio Inc., The Cooper Companies Inc., Thermo Fisher Scientific Inc., Vitrolife Sweden AB, and Yikon Genomics (Shanghai) Co., Ltd..

Market Segmentation & Coverage

This research report categorizes the Preimplantation Genetic Testing Market to forecast the revenues and analyze trends in each of the following sub-markets:

Based on Technology, market is studied across Comparative Genomic Hybridization, Fluorescence in-Situ Hybridization, Next-Generation Sequencing, Polymerase Chain Reaction, and Single-Nucleotide Polymorphism.
Based on Offering, market is studied across Instruments, Reagents & Consumables, and Software & Services.
Based on Procedure Type, market is studied across Preimplantation Genetic Diagnosis and Preimplantation Genetic Screening.
Based on Application, market is studied across Aneuploidy, Gender Identification, HLA Typing, Single Gene Disorders, Structural Chromosomal Abnormalities, and X-Linked Disorders. The Structural Chromosomal Abnormalities is further studied across Deletions, Duplications, Inversions, and Translocations.
Based on End User, market is studied across Contract Research & Manufacturing Organizations, Cryobanks, Hospitals, Diagnostic Labs, & Service Providers, and Research Laboratories & Academic Institutes.
Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Product Code: MRR-030EE48515DA

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

5.1. Market Dynamics
- 5.1.1. Drivers
  - 5.1.1.1. Significant incidences of fetal abnormalities and need for healthy and successful embryo implantation
  - 5.1.1.2. Increase in the rate of infertility and the rising number of fertility clinics worldwide
  - 5.1.1.3. Growing early diagnostic approaches coupled with increasing government support to treat genetic diseases
- 5.1.2. Restraints
  - 5.1.2.1. Limitation and risks associated with PGT
- 5.1.3. Opportunities
  - 5.1.3.1. Technological advancement in the field of preimplantation genetic analysis
  - 5.1.3.2. Emerging startup ecosystem and investments in the field of preimplantation genetic testing
- 5.1.4. Challenges
  - 5.1.4.1. Ethical constraints and Misuse of PGT
5.2. Market Segmentation Analysis
- 5.2.1. Technology: Advancements in next-generation sequencing to detect chromosomal abnormalities and single-gene disorders
- 5.2.2. Offering: Utilization of diverse offerings to optimize process conditions and derive accurate results
- 5.2.3. Procedure: Increasing deployment of preimplantation genetic diagnosis (PGD) procedures to reduce the risk of genetic disorders
- 5.2.4. Application: Wide use of preimplantation genetic testing for aneuploidy disorder
- 5.2.5. End User: Increasing adoption of PGT in healthcare research organizations for accurate diagnosis and effective treatments
5.3. Porter's Five Forces Analysis
- 5.3.1. Threat of New Entrants
- 5.3.2. Threat of Substitutes
- 5.3.3. Bargaining Power of Customers
- 5.3.4. Bargaining Power of Suppliers
- 5.3.5. Industry Rivalry
5.4. PESTLE Analysis
- 5.4.1. Political
- 5.4.2. Economic
- 5.4.3. Social
- 5.4.4. Technological
- 5.4.5. Legal
- 5.4.6. Environmental

6. Preimplantation Genetic Testing Market, by Technology

6.1. Introduction
6.2. Comparative Genomic Hybridization
6.3. Fluorescence in-Situ Hybridization
6.4. Next-Generation Sequencing
6.5. Polymerase Chain Reaction
6.6. Single-Nucleotide Polymorphism

7. Preimplantation Genetic Testing Market, by Offering

7.1. Introduction
7.2. Instruments
7.3. Reagents & Consumables
7.4. Software & Services

8. Preimplantation Genetic Testing Market, by Procedure Type

8.1. Introduction
8.2. Preimplantation Genetic Diagnosis
8.3. Preimplantation Genetic Screening

9. Preimplantation Genetic Testing Market, by Application

9.1. Introduction
9.2. Aneuploidy
9.3. Gender Identification
9.4. HLA Typing
9.5. Single Gene Disorders
9.6. Structural Chromosomal Abnormalities
- 9.6.1. Deletions
- 9.6.2. Duplications
- 9.6.3. Inversions
- 9.6.4. Translocations
9.7. X-Linked Disorders

10. Preimplantation Genetic Testing Market, by End User

10.1. Introduction
10.2. Contract Research & Manufacturing Organizations
10.3. Cryobanks
10.4. Hospitals, Diagnostic Labs, & Service Providers
10.5. Research Laboratories & Academic Institutes

11. Americas Preimplantation Genetic Testing Market

11.1. Introduction
11.2. Argentina
11.3. Brazil
11.4. Canada
11.5. Mexico
11.6. United States

12. Asia-Pacific Preimplantation Genetic Testing Market

12.1. Introduction
12.2. Australia
12.3. China
12.4. India
12.5. Indonesia
12.6. Japan
12.7. Malaysia
12.8. Philippines
12.9. Singapore
12.10. South Korea
12.11. Taiwan
12.12. Thailand
12.13. Vietnam

13. Europe, Middle East & Africa Preimplantation Genetic Testing Market

13.1. Introduction
13.2. Denmark
13.3. Egypt
13.4. Finland
13.5. France
13.6. Germany
13.7. Israel
13.8. Italy
13.9. Netherlands
13.10. Nigeria
13.11. Norway
13.12. Poland
13.13. Qatar
13.14. Russia
13.15. Saudi Arabia
13.16. South Africa
13.17. Spain
13.18. Sweden
13.19. Switzerland
13.20. Turkey
13.21. United Arab Emirates
13.22. United Kingdom

14. Competitive Landscape

14.1. Market Share Analysis, 2023
14.2. FPNV Positioning Matrix, 2023
14.3. Competitive Scenario Analysis
- 14.3.1. Natera Inc. to acquire prenatal and carrier screening assets from Invitae, to enhance patient services and market position
- 14.3.2. Thermo Fisher Scientific launches advanced sequencing tools for preimplantation genetic testing, enhancing fertility research and reproductive health outcomes
- 14.3.3. Medicover Genetics and Fimlab Laboratories Announce Partnership to Provide Genetic Testing Services in Finland
- 14.3.4. U.S. Fertility and Ovation Combine to Create IVF Services Powerhouse, Increasing Access to Fertility Services
- 14.3.5. Eurofins Genoma Announces Launch of niPGT-A, a Non-Invasive, Embryo Biopsy Free, Preimplantation Genetic Aneuploidy Screening
- 14.3.6. GenEmbryomics Introduces the Most Complete IVF Genetic Test Ever Made Available
- 14.3.7. Singaporeans Undergoing IVF to Get New Funding For Some Types of Preimplantation Genetic Testing
- 14.3.8. Australia's Fertilis Raised USD 2 Million to Automate IVF Embryo Culturing

Companies Mentioned

1. Abbott Laboratories
2. Agilent Technologies, Inc.
3. Bio-Rad Laboratories, Inc.
4. Bio-Techne Corporation
5. Bioarray S.L.
6. EUROPE IVF International s.r.o.
7. F. Hoffmann-La Roche AG
8. Genea Limited
9. GENETiKS
10. Illumina, Inc.
11. Invicta Genetics
12. Invitae Corporation
13. Juno Genetics, US Inc.
14. Laboratory Corporation of America Holdings
15. MedGenome Labs Ltd.
16. Merck KGaA
17. Natera, Inc.
18. NextGen Genetics Holdings, LLC
19. Ovation Fertility
20. PacGenomics
21. PerkinElmer, Inc.
22. Progyny, Inc.
23. Qiagen N.V.
24. Quest Diagnostics Incorporated
25. Reproductive Genetic Innovations, LLC
26. SEQUENCE46, LLC
27. Sysmex Corporation
28. Takara Bio Inc.
29. The Cooper Companies Inc.
30. Thermo Fisher Scientific Inc.
31. Vitrolife Sweden AB
32. Yikon Genomics (Shanghai) Co., Ltd.